Par to Pay $45 Million, End US Probes Over AIDS Appetite Drug

Par Pharmaceutical has agreed to pay $45 million to settle federal criminal and civil probes over its marketing and sale of a drug to treat appetite loss in AIDS patients, a spokesman for federal prosecutor Paul Fishman in New Jersey said on Tuesday.

The generic drug company is expected to plead guilty to a criminal misdemeanor charge at a Tuesday hearing before U.S. Magistrate Judge Madeline Cox Arleo in Newark, New Jersey, the spokesman said. Par's payment will be divided equally between a fine and a forfeiture, the spokesman said.

Par, based in Woodcliff Lake, New Jersey, was purchased in September by private equity firm TPG Capital for $1.9 billion.

The company has been the subject of a U.S. Department of Justice inquiry into its marketing and sales of the drug Megace ES, which is intended to improve the appetites of HIV and cancer patients.

Tuesday's accord encompasses a civil "whistleblower" lawsuit alleging that Par engaged in illegal off-label marketing of Megace ES, according to Timothy McInnis, who brought that case.

Par did not immediately respond to a request for comment.

On Monday, Par said in a filing in the Washington D.C. federal court that it had been "close to finalizing" a resolution of several pending investigations and litigations.

Last September, the company said it had set aside $45 million as its "best estimate" for a potential global settlement regarding the inquiry.

Fishman is expected to hold a news conference later Tuesday to discuss the Par settlement.

 

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.